<DOC>
	<DOC>NCT01861236</DOC>
	<brief_summary>Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina</brief_summary>
	<brief_title>Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice Written informed consent Contraindications to Firmagon Patients already on Firmagon therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>